Transcranial magnetic stimulation after thrombectomy for acute ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind, sham-controlled trial comparing active continuous theta-burst stimulation (cTBS) to a sham procedure in patients treated with endovascular thrombectomy for acute anterior-circulation ischemic stroke. Eligible adults (18–80) have terminal ICA or M1/M2 occlusions, ASPECTS ≥6 on early CT, NIHSS 6–25 before thrombectomy, pre-stroke mRS ≤1, and successful recanalization (mTICI >2b/3). Participants are randomized after thrombectomy and receive blinded active or sham transcranial magnetic stimulation with safety and functional outcomes measured during follow-up. The trial aims to determine whether early post-thrombectomy neuromodulation can improve neurologic recovery without adding unacceptable risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.
2. Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery.
3. A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.
4. Pre-stroke mRS score is ≤1.
5. NIHSS score before thrombectomy is between 6 and 25.
6. With vascular recanalization of mTICI \> 2b/3.
7. Informed consent form signed.

Exclusion Criteria:

1. Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;
2. Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and kidneys;
3. Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;
4. Head CT/MRI suggests acute cerebral infarction in both sides;
5. Patients who are pregnant or breastfeeding;
6. Patients with severe mental disorders or dementia who cannot cooperate with follow-up;
7. Patients with other severe diseases resulting in an expected survival of less than 90 days;
8. Patients who are participating in other interventional clinical studies within 30 days before the start of this study or after the onset of this condition;
9. Patients who cannot cooperate with informed consent.

Where it's running

• Xijing Hospital
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Jingjing Zhao, Dr.
• Email: zhaojing0110@126.com
• Phone: +86-29-84775365

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mobilisation After Endovascular Stroke Treatment

  This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

  Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

• AI-powered decision support to boost thrombolysis for ischemic stroke

  This trial tests whether an AI-assisted decision tool helps doctors give intravenous thrombolysis to eligible ischemic stroke patients within 24 hours at a primary hospital in China, compared with standard care.

  Recruiting Capital Medical University · Changsha, Hunan · NCT07785492

• Factors affecting outcomes after endovascular treatment for large-vessel stroke

  This study tests how different factors influence recovery after mechanical clot removal in adults with acute ischemic stroke due to large vessel blockage.

  Recruiting Sohag University · Sohag · NCT07740018

• Tegoprazan to prevent GI complications in ischemic stroke patients on antiplatelet therapy

  This trial tests whether tegoprazan can lower gastrointestinal complications in adults with ischemic stroke or TIA who are starting antiplatelet therapy.

  Recruiting at 24 sites Phase 3 Hanyang University · Busan, Busan and 23 other locations · NCT07687706

• Intra-arterial Thrombolysis After Endovascular Thrombectomy in AIS

  This trial tests whether giving intra-arterial thrombolysis with tenecteplase or alteplase after endovascular thrombectomy helps improve recovery in adults with acute ischemic stroke.

  Recruiting Phase 3 University of Calgary · Sydney, Barangaroo and 12 other locations · NCT07687056

• Intra-arterial Thrombolysis for Acute Ischemic Stroke with Medium Vessel Occlusion

  This trial tests whether delivering a clot-busting medicine directly into the brain’s medium vessels helps improve outcomes for adults with acute ischemic stroke caused by MeVO, on top of standard care.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07668323

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.